Literature DB >> 16399037

Contrast enhancement in electron beam tomography of the heart: comparison of a monomeric and a dimeric iodinated contrast agent in 59 patients.

Christian N H Enzweiler1, Sebastian Höhn, Matthias Taupitz, Alexander E Lembcke, Till H Wiese, Bernd Hamm, Dietmar E Kivelitz.   

Abstract

RATIONALE AND
OBJECTIVES: The aim of the study is to determine whether intravascular time-density course and visualization of the coronary arteries differ with use of a hyperosmolar monomeric versus an iso-osmolar dimeric contrast agent in electron beam tomography (EBT) of the heart.
MATERIALS AND METHODS: Fifty-nine patients underwent EBT of the coronary arteries using the monomeric ioversol or the dimeric iodixanol at the same concentration of 320 mg I/mL. Contrast volume was determined relative to body surface area and injected over 40 seconds. Intravascular time-density curves were created for quantitative analysis. For qualitative assessment, visualization of coronary arteries on axial scans and three-dimensional reconstructions was scored. Patients were matched for contrast flow, transit time, and mean pulse rate for statistical analysis.
RESULTS: Ioversol produced a significantly greater increase in intravascular density for up to 30 seconds after injection (P < .01) compared with iodixanol. No difference between the two contrast media was seen in the qualitative assessment.
CONCLUSION: Monomeric and dimeric contrast media differ in their time-density curves at coronary EBT, a reason for which is not apparent. Qualitative evaluation of coronary arteries is not affected by this difference.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16399037     DOI: 10.1016/j.acra.2005.09.089

Source DB:  PubMed          Journal:  Acad Radiol        ISSN: 1076-6332            Impact factor:   3.173


  1 in total

1.  Dimethyl 5-nitro-isophthalate.

Authors:  Min-Hao Xie; Pei Zou; Yong-Jun He; Ya-Ling Liu; Biao Huang
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2008-08-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.